Claims

1. A pharmaceutical composition comprising:

an anti-Aβ antibody or Aβ-binding fragment thereof at a concentration of 50 mg/ml to 250 mg/ml; Arg.HCl at a concentration of 75 mM to 175 mM; methionine at a concentration of 5 mM to 15 mM; histidine at a concentration of 10 mM to 30 mM; polysorbate-80 (PS80) at a concentration (w/v) of 0.01% to 0.1%; and wherein the composition has a pH of 5.2 to 6.0.

2. A pharmaceutical composition comprising:

an anti-Aβ antibody or Aβ-binding fragment thereof at a concentration of 50 mg/ml to 250 mg/ml; a thiol-containing antioxidant selected from the group consisting of GSH, GSSG, the combination of GSH and GSSG, cystine, and cysteine; Arg.HCl at a concentration of 75 mM to 175 mM; methionine at a concentration of 5 mM to 15 mM; histidine at a concentration of 10 mM to 30 mM; polysorbate-80 (PS80) at a concentration (w/v) of 0.01% to 0.1%; and wherein the composition has a pH of 5.2 to 6.0.

3. The pharmaceutical composition of claim 1 or 2, wherein the composition comprises the anti-Aβ antibody or Aβ-binding fragment thereof at a concentration of 175 mg/ml.

4. The pharmaceutical composition of any one of claims 1 to 3, wherein the composition comprises the anti-Aβ antibody or Aβ-binding fragment thereof at a concentration of 100 mg/ml.

5. The pharmaceutical composition of any one of claims 1 to 4, wherein the composition has a pH of 5.3 to 5.7.

6. The pharmaceutical composition of claim 1, wherein the composition comprises the anti-Aβ antibody or the Aβ-binding fragment thereof at a concentration of 100 mg/ml; Arg.HCl at a concentration of 150 mM; methionine at a concentration of 10 mM; histidine at a concentration of 10 mM to 30 mM; polysorbate-80 (PS80) at a concentration (w/v) of 0.01% to 0.1%; and wherein the composition has a pH of 5.2 to 6.0.

7. The pharmaceutical composition of claim 1, comprising the anti-Aβ antibody or the Aβ-binding fragment thereof at a concentration of 100 mg/ml; Arg.HCl at a concentration of 150 mM; methionine at a concentration of 10 mM; histidine at a concentration of 20 mM; and polysorbate-80 (PS80) at a concentration (w/v) of 0.05%, wherein the composition has a pH of 5.5

8. The pharmaceutical composition of claim 2, comprising: the anti-Aβ antibody or the Aβ-binding fragment thereof at a concentration of 175 mg/ml; Arg.HCl at a concentration of 150 mM; methionine at a concentration of 10 mM; thiol-containing antioxidant is at a concentration of 0.02 mM to 4 mM; histidine at a concentration of 10 mM to 30 mM; polysorbate-80 (PS80) at a concentration (w/v) of 0.01% to 0.1%; and wherein the composition has a pH of 5.2 to 6.0.

9. The pharmaceutical composition of claim 2, comprising: the anti-Aβ antibody or the Aβ-binding fragment thereof at a concentration of 175 mg/ml; Arg.HCl at a concentration of 150 mM; methionine at a concentration of 10 mM; thiol-containing antioxidant is at a concentration of 0.02 mM to 4 mM; histidine at a concentration of 20 mM; and polysorbate-80 (PS80) at a concentration (w/v) of 0.05%, wherein the composition has a pH of 5.5.

10. The pharmaceutical composition of any one of claims 2, 8, and 9, wherein the thiol-containing antioxidant is a combination of GSH and GSSG, wherein the GSH and GSSG together have a combined concentration of 0.4 mM.

11. The pharmaceutical composition of any one of claims 1 to 10, wherein:
the VH comprises a sequence at least 80% identical to SEQ ID NO:7 and the VL comprises a sequence at least 80% identical to SEQ ID NO:8.

12. The pharmaceutical composition of any one of claims 1 to 10, wherein:
the VH comprises a sequence at least 90% identical to SEQ ID NO:7 and the VL comprises a sequence at least 90% identical to SEQ ID NO:8.

13. The pharmaceutical composition of any one of claims 1 to 10, wherein:
the VH comprises the amino acid sequence set forth in SEQ ID NO:7 and the VL

comprises the amino acid sequence set forth in SEQ ID NO:8.

14. The pharmaceutical composition of any one of claims 1 to 13, wherein the anti-Aβ antibody comprises a human IgG1 constant region.

15. The pharmaceutical composition of any one of claims 1 to 14, wherein the anti-Aβ antibody comprises an immunoglobulin heavy chain and an immunoglobulin light chain, wherein:
the heavy chain comprises a sequence at least 80% identical to SEQ ID NO:9 and the light chain comprises a sequence at least 80% identical to SEQ ID NO:10.

16. The pharmaceutical composition of any one of claims 1 to 14, wherein the anti-Aβ antibody comprises an immunoglobulin heavy chain and an immunoglobulin light chain, wherein:
the heavy chain comprises a sequence at least 90% identical to SEQ ID NO:9 and the light chain comprises a sequence at least 90% identical to SEQ ID NO:10.

17. The pharmaceutical composition of any one of claims 1 to 14, wherein the anti-Aβ antibody comprises an immunoglobulin heavy chain and an immunoglobulin light chain, wherein:
the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:9 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:10.

18. Use of the pharmaceutical composition of any one of claims 1 to 17 in the manufacture of a medicament for the treatment of (i) mild cognitive impairment; or (ii) Alzheimer's disease.

19. The use of claim 18, wherein the medicament is to be administered subcutaneously or intravenously to the human subject.

20. A pharmaceutical composition of any one of claims 1 to 17 for use in therapy.